Press Releases

Date Title and Summary Additional Formats
Toggle Summary Assembly Biosciences to Present at the J.P. Morgan Healthcare Conference
INDIANAPOLIS , Jan. 04, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the
View HTML
Toggle Summary Assembly Biosciences Appoints Sue Mahony, PhD to Board of Directors
INDIANAPOLIS , Dec. 18, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the
View HTML
Toggle Summary Assembly Biosciences Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
INDIANAPOLIS , Dec. 08, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the
View HTML
Toggle Summary Assembly Biosciences to Present at the Jefferies London Healthcare Conference
INDIANAPOLIS , Nov. 08, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the
View HTML
Toggle Summary Assembly Biosciences Announces Pricing of $60 Million Offering of Common Stock
INDIANAPOLIS , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB) ("Assembly" or the "Company"), a clinical-stage biotechnology company advancing a new class of oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel oral live
View HTML
Toggle Summary Assembly Biosciences Announces Proposed Underwritten Offering of Common Stock
INDIANAPOLIS , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB) ("Assembly" or the "Company"), a clinical-stage biotechnology company advancing a new class of oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel oral live
View HTML
Toggle Summary Assembly Biosciences Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
INDIANAPOLIS , Oct. 05, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the
View HTML
Toggle Summary Assembly Biosciences Announces 2017 AASLD Presentations
INDIANAPOLIS , Oct. 02, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the
View HTML
Toggle Summary Assembly Biosciences Selects Next-Generation CpAM Candidate for Advancement into Clinical Development
INDIANAPOLIS , Sept. 25, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the
View HTML
Toggle Summary Assembly Biosciences Announces September Conference Participation
INDIANAPOLIS , Aug. 31, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the
View HTML